SCHEMBL11943569

SCHEMBL11943569

CCCCCCSc1c(N2CCN(S(=O)(=O)C(C)C)CC2)cnn(-c2cc(F)cc(F)c2)c1=O

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.38
NPSR1 Q6W5P4 2/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CYP17A1 P05093 3/20 0.36
CYP21A2 P08686 3/20 0.36
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35
PPARG P37231 1/20 0.35
NCOA2 Q15596 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35
ALDH1A1 P00352 3/20 0.34
DCTPP1 Q9H773 1/20 0.34
CYP11B1 P15538 1/20 0.33
NPY5R Q15761 1/20 0.33
CA12 O43570 1/20 0.32
CA1 P00915 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943570 0.90 ALDH1A1 (0.44) MAPTNPSR1LMNASMN1; SMN2L3MBTL1
SCHEMBL11944881 0.88 MAPT (0.38) MAPTNPSR1LMNASMN1; SMN2L3MBTL1
SCHEMBL11943800 0.85 CYP17A1 (0.40) MAPTNPSR1LMNASMN1; SMN2CYP17A1
SCHEMBL11943690 0.85 CYP17A1 (0.40) MAPTNPSR1LMNASMN1; SMN2CYP17A1
SCHEMBL11943804 0.83 MAPT (0.41) MAPTNPSR1LMNASMN1; SMN2CYP17A1
SCHEMBL11945131 0.83 MAPT (0.38) MAPTNPSR1LMNACYP17A1CYP21A2
SCHEMBL11943621 0.81 MAPT (0.38) MAPTNPSR1CYP17A1CYP21A2POLB
SCHEMBL11943579 0.79 ALDH1A1 (0.44) MAPTNPSR1LMNASMN1; SMN2CYP17A1
SCHEMBL11943585 0.79 ALDH1A1 (0.42) MAPTNPSR1LMNASMN1; SMN2CYP17A1
SCHEMBL17058327 0.78 POLB (0.41) MAPTNPSR1LMNASMN1; SMN2CYP17A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA MAPT 2295/4885NPSR1 4251/4885LMNA 929/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.